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Nuclear factor (NF) 90 and NF45 are each 
zinc-fi  nger DNA- and RNA-binding proteins 
purifi  ed and cloned from activated T cells based 
on their specifi   c binding to the A-T–rich 
  purine-box/antigen receptor response element 
(ARRE)/NFAT site in the IL-2 promoter 
(1, 2). NF90 also contains two double-stranded 
RNA-binding motifs that bind IL-2 and other 
RNAs (3–5). Antisera to NF90 and NF45 spe-
cifi  cally inhibited ARRE/NFAT DNA bind-
ing and in vitro transcription (2). NF90 and 
NF45 copurify with two systemic lupus ery-
thematosis autoantigens, Ku80 and Ku70, and 
the catalytic subunit of DNA-dependent pro-
tein kinase (6). Monoclonal antibodies against 
Ku80 and Ku70 specifi  cally inhibited ARRE 
DNA binding (7, 8).
Proteins with double-stranded RNA-binding 
motifs—such as NF90 (also referred to as IL 
enhancer binding factor 3), RNA helicase A, 
adenosine-to-inosine editase (RNA-specifi  c 
adenosine deaminase [ADA]), staufen, protein 
kinase R, and Dicer—can bind structured nucleic 
acids and regulate gene expression at the levels 
of transcription, RNA processing and transport, 
translation, and RNA interference (9). NF90 
regulates transcription (10–12), posttranscrip-
tional RNA stabilization (3, 5), nuclear export 
(3), and translation (4, 13). NF90 has been impli-
cated in host antiviral responses and as a cellular 
cofactor involved in viral replication and trans-
lation (9, 13, 14).
The ARRE site serves a unique role in 
regulating IL-2 transcription: a specifi  c tran-
scriptional repressor preexisting in the nucleus 
of resting T cells is converted during T cell 
  activation into a potent transcriptional activator 
(15). DNA-footprinting experiments demon-
strated that proteins bound to the distal ARRE-2 
site in the IL-2 proximal promoter in resting 
Jurkat and EL-4 T cells and T cell activa-
tion expanded the footprint of this purine-box 
NF90 regulates inducible IL-2 gene 
expression in T cells
Lingfang Shi,1 Wayne R. Godfrey,2 Joseph Lin,1 Guohua Zhao,1 
and Peter N. Kao1
1Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA 94305
2Cellular Immunology, Dendreon Corp., Seattle, WA 98121
Activation of T cells induces the production of T cell growth and survival factor interleukin 
(IL) 2. Regulatory T cells intrinsically fail to induce IL-2 expression upon activation and can 
suppress IL-2 production in conventional T cells. Thus, the control of IL-2 expression is 
critically important to T cell immune responses, yet the mechanisms remain incompletely 
understood. Nuclear factor (NF) 90 is a zinc-fi  nger DNA- and double-stranded RNA-
binding protein subunit that binds specifi  cally to the antigen receptor response element 
(ARRE)/NF of activated T cells target sequence in the IL-2 proximal promoter. Inducible 
binding of NF90 to the IL-2 promoter in vivo is shown by chromatin immunoprecipitation. 
NF90 gene-targeted mice exhibit perinatal lethality. Compared with newborn NF90+/+ 
mice, newborn NF90−/− mice demonstrate severe impairment of IL-2 expression. 
Compared with wild-type cells, T cells defi  cient in NF90 are impaired in ARRE and IL-2 
transcriptional activation and IL-2 mRNA stabilization. Fetal liver cells from NF90 
gene-targeted mice were transplanted into irradiated adult recombination activating 
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  regulator complex (16, 17). The ARRE site was proposed 
as key for regulating chromatin melting and providing con-
certed access of all other transcription factors to the IL-2 
promoter (18). This model predicts that targeted disruption 
of the genes that encode critical regulators operating at the 
  purine-box/NFAT site in the IL-2 promoter may confer 
phenotypes of defective IL-2 transcription and T cell activa-
tion and may exhibit T cell immunodefi  ciency in vivo.
To elucidate the roles of NF90 in development and im-
mune regulation, we generated mice with a targeted disrup-
tion of NF90. NF90−/− mice die within 6 h of birth because 
of diaphragmatic respiratory failure related to insuffi   cient ex-
pression of the myogenic regulators MyoD, myogenin, and 
p21Cip1/Waf1 (5). To circumvent the perinatal lethality of 
the NF90-defi  cient mice, we transplanted NF90 fetal liver 
cells into irradiated recombination activating gene (RAG)–
2−/−/IL-2Rγ−/− mice that lack T cells, B cells, and NK cells 
and characterized immune reconstitution and function in 
the NF90-RAGγ chimeric mice. In this report, we demon-
strate that NF90 inducibly binds to the IL-2 promoter and 
regulates ARRE/NFAT and IL-2 transcriptional activation, 
IL-2 mRNA stability, IL-2 gene expression, and peripheral 
T lymphocyte survival in vivo.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
NF90 binds specifi  cally to the IL-2 promoter in vivo 
in activated T cells
We used chromatin immunoprecipitation (ChIP) to charac-
terize in vivo binding of NF90 to the IL-2 proximal pro-
moter, to IL-2 intron 3 (2.5 kB removed), and to the ADA 
origin of DNA replication to which Ku80 and Ku70 specifi  -
cally bind in vivo (Fig. 1) (19). Primary mouse spleen cells 
were nonstimulated or stimulated for 4 h with PMA + iono-
mycin (PMA/Iono) and treated with 1% formaldehyde to 
cross-link transcription factors to their chromatin targets in 
vivo. Genomic PCR of sheared and restricted input chroma-
tin demonstrated equal amplifi  cation of all targets from non-
stimulated and stimulated cells (Fig. 1 A). We performed 
NF90 ChIP using a monoclonal antibody and showed spe-
cifi  c binding to the IL-2 proximal promoter in vivo that in-
creased upon stimulation (Fig. 1, B, lane 2 vs. lane 1), and no 
binding to IL-2 intron 3 (Fig. 1 B, lanes 3 and 4). NF90 
bound equally to the ADA origin of DNA replication in 
nonstimulated and stimulated spleen cells (Fig. 1 B, lanes 5 
and 6). Control antibody against hemagglutinin (HA) epitope 
did not precipitate the IL-2 promoter, intron 3, or ADA 
chromatin targets in our experimental conditions (Fig. 1 C). 
This ChIP result validates our original purifi  cation  using 
EMSA that identifi   ed NF90 and NF45 as subunits of an 
  inducible ARRE/NFAT DNA-binding complex in the 
  nucleus of Jurkat T cells (1).
NF90 genotype determines phenotype of maximal IL-2 
gene expression
Adult NF90 heterozygous mice are indistinguishable from wild-
type NF90 littermates in terms of size, activity, and   longevity. 
We examined whether adult NF90 heterozygous mice might 
express less IL-2 than wild-type littermates. Compared with 
NF90+/+ mice, thymocytes and splenocytes from NF90+/− 
mice stimulated with PMA/Iono for 6, 12, and 18 h produced 
 50% less IL-2 (Fig. 2 A). We also characterized maximal 
IL-2 gene expression by newborn NF90+/+, NF90+/−, and 
NF90−/− littermates (Fig. 2 B). Compared with NF90+/+ 
mice, lymphocytes from NF90+/− and NF90−/− mice stimu-
lated with PMA/Iono for 6 h mice demonstrat  ed moderate 
and severe impairment of IL-2   expression. The substantial 
reduction in IL-2 expression in NF90 gene-targeted mice as 
early as 6 h suggests that expression levels of NF90 regulate 
transcriptional activation of the IL-2 gene.
NF90 fetal liver RAG-2−/−/IL-2R𝗄−/− chimeric 
mice characterization
We transplanted NF90 fetal liver cells, enriched in hematopoi-
etic stem cells, into irradiated adult RAG-2−/−/IL-2Rγ−/− 
mice that lack T cells, B cells, and NK cells. The resultant 
chimeric mice developed T and B lymphocytes, allowing us 
to determine the contributions of NF90 to T cell homeostasis, 
activation, and IL-2 gene expression.
We performed four independent NF90 fetal liver transplan-
tation experiments that generated 21 NF90-RAGγ chimeric 
mice. A total of 10 NF90−/−-RAGγ animals were compared 
with 10 NF90+/+- or NF90+/−-RAGγ chimeric littermates. 
Complete blood counts demonstrated no substantial defects 
in the reconstitution of erythroid, myeloid, or  megakaryocytic 
lineages. The most consistent defect we observed in NF90−/−-
RAGγ chimeras was lymphocytopenia (Table I).
Flow cytometry analyses of T cell development
NF90-RAGγ chimeric mice were killed 14 wk after trans-
plantation. The thymi and spleens in all NF90-RAGγ chimeric 
Figure 1.  NF90 binds specifi  cally to the IL-2 promoter in vivo in 
activated T cells. Spleen cells were nonstimulated (lanes 1, 3, and 5; N) 
or stimulated for 4 h with PMA/Iono (lanes 2, 4, and 6; S), and nuclear 
proteins were cross-linked to chromatin in vivo with 1% formaldehyde. 
(A) Sheared and restricted chromatin was used as a template for PCR 
amplifi  cations of IL-2 proximal promoter (lanes 1 and 2), IL-2 intron 3 
(lanes 3 and 4), and ADA origin of replication sequences (lanes 5 and 6). 
(B) NF90 ChIP. (C) HA epitope ChIP.JEM VOL. 204, May 14, 2007  973
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Figure 2.  Targeted disruption of NF90 impairs T cell IL-2 gene 
expression and T cell homeostasis. (A) Thymocytes and splenocytes 
were isolated from adult NF90+/+ and NF90+/− littermate mice and stim-
ulated with for 6–18 h with PMA/Iono, and secreted IL-2 was measured 
by ELISA. The data are representative of two independent pairs of litter-
mates. NF90+/− IL-2 reduction was signifi  cant (P < 0.05). (B) Thymocytes 
and splenocytes were isolated from two newborn NF90+/+, two NF90+/−, and 
one NF90−/− littermate mice and stimulated for 6 h with PMA/Iono, 
and IL-2 was measured. IL-2 reduction was signifi  cant (P < 0.001). Non-
stimulated cells produced no detectable IL-2. (C) Immune reconstitution 
analysis of NF90-RAGγ mice. Representative fl  ow cytometry of CD4+ and 
CD8+ lymphocytes in the thymus and spleen of NF90−/−- and NF90+/+-
RAG−/−/IL-2Rγ−/− chimeric mice. NF90−/−-RAGγ chimera yielded 107 
thymocytes, 4.2 × 108 splenocytes, and 1,666 peripheral lymphocytes per 
mm3, and NF90+/+-RAGγ chimera yielded 107 thymocytes, 4.5 × 108 
splenocytes, and 3,455 peripheral lymphocytes per mm3. Recipient mice 
received 900 rads conditioning radiation and were killed at 14 wk after 
transplantation with NF90 E14 fetal liver cells. Peripheral blood lym-
phocyte subset analyses of the same mice at 9 wk after transplantation 
demonstrated a nearly complete absence of circulating CD4+ and CD8+ 
T cells associated with the NF90−/− genotype (row 3). Spleen cells were 
gated on CD3 and analyzed for expression of CD4 and CD25 in nonstimu-
lated conditions (row 4) and after 24 h of stimulation with anti-CD3 
(row 5). The percentage of cells in each quadrant is shown. (D) Impaired 
IL-2 secretion in NF90−/−-RAGγ compared with NF90+/−- or NF90+/+-
RAGγ chimeric mice. Single-cell suspensions of thymocytes, splenocytes, 
and CD4+ T cells from individually numbered chimeras were stimulated 
with PMA/Iono or anti-CD3 + CD28. After 16 h, secreted IL-2 was 
measured. IL-2 reduction in the NF90−/−-RAGγ chimeric T cells was 
signi fi  cant (P < 0.02). Data in A, B, and D represent the mean ± SD.974  NF90 REGULATES IL-2 TRANSCRIPTION AND MRNA STABILITY | Shi et al.
mice were substantially larger than in adult RAGγ-null mice 
and were approximately two thirds the size of wild-type donor 
mice. We analyzed surface expression of CD4, CD8, CD3, 
and CD45R-B220 on thymocytes and splenocytes (Fig. 2 C). 
The thymi of all NF90-RAGγ chimeric mice contained a 
major population of CD4+ and CD8+ (double-positive) thy-
mocytes (Fig. 2 C, row 1). The spleens of all NF90-RAGγ 
chimeric mice showed maturation of T cells to CD4+ or 
CD8+ (single-positive) T cells. B cells represented 70–80% 
of splenic lymphocytes (Fig. 2 C, row 2). We consistently 
observed a modest decrease in splenic CD4+ T cells and a 
moderate decrease in CD8+ T cells between the NF90−/−-
RAGγ and NF90+/−- or NF90+/+-RAGγ chimeras (Fig. 
2 C, row 2). The reconstitution of T cells and B cells in the 
NF90−/−-RAGγ chimeras demonstrated that NF90 is not 
absolutely required for T or B cell development.
Analyses of lymphocyte subsets in peripheral blood at 
4 and 9 wk after transplantation revealed no reconstitution of 
T cells in NF90−/−-RAGγ chimeras compared with NF90+/+- 
and NF90+/−-RAGγ chimeras. We observed severe defi  -
ciencies of CD4+ and CD8+ T cells only in NF90−/−-RAGγ 
chimeric animals (Fig. 2 C, row 3). This T cell lymphocyto-
penia was present in fi  ve out of six NF90−/−-RAGγ chimeras 
compared with zero out of seven NF90+/−- or NF90+/+-
RAGγ chimeras. The residual lymphocytes in the peripheral 
circulation of NF90−/−-RAGγ chimeras were predominantly 
B cells. From this result, we infer that NF90 is necessary for 
T cell survival in the blood but not in the spleen.
Spleen cells were analyzed for the proportion of 
CD4+CD25+ regulatory T cells (Fig. 2 C, rows 4 and 5). 
Compared with NF90+/+-RAG chimeras, NF90−/−-RAG 
chimeras showed an increased proportion of CD4+CD25+ 
regulatory T cells in nonstimulated spleen cells and a de-
creased proportion of regulatory T cells after anti-CD3 stim-
ulation. The results shown are representative of multiple 
NF90-RAG chimeric mice and support our hypothesis that 
NF90 modulates T cell immune responses.
NF90−/−-RAG chimeric T cells demonstrate impaired 
secretion of IL-2
We characterized IL-2 production by NF90-RAGγ chimeric 
thymocytes, splenocytes, and purifi  ed splenic CD4+ T cells in 
response to primary stimulations for 16 h with PMA/Iono and 
anti-CD3 + CD28 (Fig. 2 D). Stimulated NF90−/−-RAGγ 
chimeric T cells (eight mice) consistently demonstrated severely 
reduced IL-2 expression compared with NF90+/+ or NF90+/−-
RAGγ T cells (seven littermate mice).
NF90−/− thymocytes are impaired in ARRE/NFAT 
transcriptional activation
To address the mechanisms of impaired IL-2 expression in T 
cells lacking NF90, we characterized transcriptional activation 
of an ARRE/NFAT luciferase reporter gene transfected into 
NF90+/+, NF90+/−, and NF90−/− thymocytes (Fig. 3 A). 
Compared with NF90+/+ and NF90+/− cells, NF90−/− thy-
mocytes demonstrated severe impairment of ARRE/NFAT 
transcriptional activation upon stimulation (Fig. 3 A).
NF90 transcriptionally activates an ARRE/NFAT luciferase 
reporter gene in Jurkat T cells
We recently reported that transgenic overexpression of NF45 
in Jurkat T cells conferred 120-fold enhancement of IL-2 
  promoter– and NFAT-luciferase reporter gene activation 
(20). In this paper we demonstrate that stable transgenic expres-
sion of NF90 in Jurkat T cells is associated with 70–80-fold 
specifi  c enhancement of ARRE/NFAT luciferase reporter 
gene activation in nonstimulated and PMA/Iono-stimulated 
T cells (Fig. 3 B). These results indicate that NF90 and NF45 
specifi   cally transactivate the ARRE sequence in activated 
T cells.
NF90−/− thymocytes are impaired in IL-2 gene transcription
We performed ChIP to examine recruitment and binding of 
the large subunit of RNA polymerase II to the IL-2 proximal 
promoter in nonstimulated and stimulated NF90+/+ and 
Table I.  Complete blood counts of NF90 donors, RAG-2−/−/IL-2Rγ−/− recipients, and NF90-RAG chimeric mice at 14 wk after 
transplantation of fetal liver stem cells
WBC 
K/𝗍l
Neutrophils 
absolute
Lymphocytes 
absolute
Hemoglobin 
gm/dL
Platelets 
K/𝗍l
Donor NF90+/+ 8 400 7,600 16.1 732
Donor NF90+/− 8.4 1,590 6,529 15.0 1,233
RAG recipient 0.4 L 180 180 L 12.9 L 876
(−/−) BMT 3.8 L 2,172 1,295 L 13.1 L 1,429
(−/−) BMT 1.2 L 234 913 L 13.5 L 1,277
(−/−) BMT 2.5 L 446 2,009 L 13.4 L 1,177
(−/+) BMT 7.8 853 6,510 13.3 L 943
(+/+) BMT 7.3 584 6,570 13.7 608
(+/+) BMT 7.1 1,343 5,090 12.1 L 1,430
(−/−) BMT2 2.4 L 643 1,666 L 12.8 L 883
(+/+) BMT2 6.9 2,971 3,455 13.5 L 1,723
Conditioning radiation for BMT was 450 cGy and for BMT2 was 900 cGy. Abnormal values are identifi  ed by L (low) and shown in bold.JEM VOL. 204, May 14, 2007  975
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NF90−/− thymocytes. In nonstimulated T cells, we observed 
no binding of RNA pol II to the chromatin at the IL-2 prox-
imal promoter, consistent with a closed chromatin conforma-
tion and no transcription. Wild-type thymocytes stimulated 
with anti-CD3/CD28 showed prominent induction of RNA 
pol II binding to the IL-2 promoter, consistent with tran-
scriptional activation (Fig. 3 C, lanes 2 and 4 vs. lanes 1 and 3). 
In contrast, NF90-defi  cient thymocytes showed substan-
tially reduced binding of RNA pol II to the IL-2 promoter 
upon stimulation (Fig. 3 C, lanes 6 and 8 vs. lanes 2 and 4). 
Figure 3.  NF90 regulates ARRE/NFAT and IL-2 transcriptional 
activation and binds to and regulates IL-2 mRNA stability. (A) Pri-
mary cultured thymocytes from NF90+/+, NF90+/−, and NF90−/− litter-
mates were nucleofected with 3× ARRE/NFAT fi  refl  y luciferase and EF-1α 
Renilla luciferase reporter plasmids. Lysates were prepared from non-
stimulated (NS) and 6-h PMA/Iono-stimulated (ST) cells and analyzed for 
the ratio of fi  refl  y/Renilla luciferase activities. Data represent the mean ± 
SD. (B) Jurkat T cells stably expressing NF90 cDNA were established. Con-
trol and NF90 T cells were transiently cotransfected with 3× ARRE/NFAT 
fi  refl  y luciferase and EF-1α Renilla luciferase. Lysates prepared from NS 
and ST cells were analyzed for luciferase activities. *, P < 0.05 for NF90 
versus control (n = 4). (C) IL-2 promoter ChIP using mAB 8WG16 to RNA 
polymerase II. Thymocytes from newborn NF90+/+ or NF90−/− mice (two 
littermate animals for each genotype) were nonstimulated (NS) or stimu-
lated (ST) for 6 h with anti-CD3/CD28, and RNA pol II ChIP was performed. 
(D) Northwestern analysis. Mouse brain extracts and recombinant NF90 
protein were fractionated by SDS-PAGE, transferred to nitrocellulose, and 
hybridized with 32P-labeled mouse IL-2 3′ UTR RNA probe (558–939 nt). 
(E) RT-PCR analysis of IL-2 mRNA induction and stability in NF90+/+ and 
NF90−/− splenocytes nonstimulated (N) or stimulated (S) for 6 h with 
anti-CD3/CD28. At 6 h, actinomycin D (A) was added, and the remaining 
IL-2 mRNA after 30 min was determined. (F) Semilog plot of IL-2 mRNA 
present at 0 and 30 min after addition of actinomycin D. The data shown 
are the mean and SD of two replicates.976  NF90 REGULATES IL-2 TRANSCRIPTION AND MRNA STABILITY | Shi et al.
This result supports our conclusion that NF90 regulates in-
ducible IL-2 transcription.
NF90 binds to and stabilizes IL-2 RNA
We used Northwestern blotting to demonstrate that NF90 
is a principal IL-2 3′ untranslated region (UTR) RNA-
binding protein (Fig. 3 D) (3). Brain extracts are suitable for 
these studies because NF90 is highly expressed in the brain 
(5), and IL-2 is expressed in rodent brains (21). A 90-kD 
protein with the same electrophoretic mobility and IL-2 
RNA-binding properties as recombinant NF90 is present 
in NF90+/+ extracts and is absent in extracts prepared from 
NF90−/− mice. We observed similar results with NF90−/− 
neonatal thymocytes and a shorter IL-2 RNA probe that 
contains the four proximal ARREs (unpublished data). We 
examined IL-2 mRNA stability in splenocytes from newborn 
NF90+/+ and NF90−/− mice. Upon stimulation with anti-
CD3/CD28, NF90+/+ splenocytes prominently induced IL-2 
mRNA (Fig. 3 E, lanes 2 and 5 vs. lanes 1 and 4), whereas 
NF90−/− splenocytes show reduced IL-2 induction (Fig. 3 E, 
lanes 8 and 11 vs. lanes 2 and 5). Transcription was blocked 
after 6 h of stimulation by the addition of actinomycin D 
(22). Compared with NF90+/+ splenocytes, NF90−/− sple-
nocytes showed faster disappearance of IL-2 mRNA after 
30 min (Fig. 3 F). Assuming fi  rst order exponential decay 
kinetics, the IL-2 mRNA half-life in NF90+/+ mice is 37 min, 
whereas the IL-2 mRNA half-life in NF90−/− mice is 12 min. 
Thus, NF90 binds to and stabilizes newly transcribed IL-2 RNA, 
thereby posttranscriptionally enhancing IL-2 gene expression.
We propose that NF90 regulates and facilitates rapid 
  expression of IL-2 and other important, tightly controlled 
genes (including MyoD and p21Cip1) (5). T cell activation 
triggers IL-2 chromatin remodeling that increases the bind-
ing of NF90 and RNA polymerase II to the IL-2 proximal 
promoter in vivo, as revealed by ChIP. NF90 regulates 
transcriptional activation through the ARRE sequence in 
the IL-2 proximal promoter in activated T cells. NF90-
defi  cient thymocytes exhibit specifi  c impairment of ARRE/
NFAT-regulated transcriptional activation and binding of 
RNA pol II to the IL-2 promoter upon stimulation. Bind-
ing of newly transcribed IL-2 RNA to NF90 stabilizes the 
transcript against degradation (3). Operating as an RNA 
chaperone, NF90 regulates nuclear export of IL-2 RNA 
and can associate with ribosomes and regulate protein trans-
lation (4, 13).
Purine-box regulator ARRE DNA-binding subunits 
NF90, NF45, Ku80, and Ku70 (1, 2, 7, 8) are distinct from 
the  120-kD NFAT proteins isolated from T cell cytoplasm 
(23). Both NF90 and NFAT proteins can specifi  cally bind 
to the same ARRE sequence in vitro. Our ChIP results 
demonstrate inducible binding of NF90 to the IL-2 proxi-
mal promoter in vivo. Targeted disruptions of individual 
NFAT proteins failed to impair IL-2 gene expression, which 
prompted the characterization of NFATc1 and NFATc2 
double-knockout (DKO) fetal liver–RAG chimeric mice 
(24). These DKO mice showed normal reconstitution of T 
cells and B cells, but in vitro cultured DKO T cells showed 
defi  cient IL-2 production when restimulated with anti-CD3. 
It will be important to elucidate the relative contributions of 
NF90 and NFATs to regulating the individual steps of IL-2 
gene expression.
Our study identifi  es NF90 as an important regulator of 
T cell IL-2 transcription, mRNA stability, and gene expres-
sion and, therefore, a novel target for therapeutic modulation 
of T cell immune responses. The T cell lymphocytopenia 
  associated with homozygous defi  ciency of NF90 may be a 
consequence of attenuated proliferation or survival of circu-
lating T cells caused by impaired expression of IL-2 or other 
genes. Future studies should also address the roles of NF90 as 
a host cellular factor that may be subverted during viral 
pathogenesis (9, 14, 25).
MATERIALS AND METHODS
Animal studies. Animal studies were approved by the Stanford University 
Administrative Panel on Laboratory Animal Care.
ChIP. Mouse spleen cells (C57BL/6) were nonstimulated or stimulated 
for 4 h with 20 ng/ml PMA (Sigma-Aldrich) + 2 μM Iono (Calbiochem). 
106 thymocytes per condition from newborn NF90+/+ or NF90−/− mice 
were nonstimulated or stimulated for 6 h with anti-CD3 + anti-CD28 (1 μg/ml 
each). Formaldehyde cross-linking and ChIP were performed as previously 
described (19). Antibodies were against NF90 (mAb DRBP76; Becton 
Dickinson), HA (sc-805; Santa Cruz Biotechnology, Inc.), and the large 
subunit of RNA polymerease II (8WG16; Covance). PCR primers were 
as follows: IL-2 proximal promoter (299 bp), (forward) 5′-C  T  G  C  C  A  C  C-
T  A  A  G  T  G  T  G  G  G  C  T  A  A  C  C  C  G  A  C  C  -3′ and (reverse) 5′-G  C  A  T  G  C  T  G  T  A-
C  A  T  G  C  C  T  G  C  A  G  G  A  C  T  T  G  A  G  G  -3′; IL-2 intron 3 (424 bp), (forward) 
5′-C  C  A  C  A  A  T  G  T  G  G  G  T  G  G  G  T  C  A  C  T  G  C  A  A  T  T  G  A  A  C  -3′ and (reverse) 
5′-G  T  T  A  G  G  C  C  A  C  T  C  T  A  G  T  G  A  G  C  T  C  T  T  C  T  G  G  C  -3′; and ADA origin 
of DNA replication (268 bp), (forward) 5′-C  T  G  A  G  A  C  T  A  T  C  C  T  C  C  A  G-
G  T  C  T  T  C  T  A  A  T  G  G  G  G  -3′ and (reverse) 5′-G  G  A  T  G  A  C  C  C  T  T  T  C  A  T  G-
G  C  T  G  C  C  T  A  T  G  A  C  C  A  A  C  A  G  -3′. PCR amplifi  cations used a three-step 
protocol with annealing temperatures of 58°C or 59°C and 35 cycles.
NF90 fetal liver–RAG𝗄 transplantations. NF90 gene-targeted donor 
mice and RAG-2−/−/IL-2Rγ−/− recipient mice were maintained on a 
C57BL/6 background. NF90+/− mice were intercrossed and killed at 
E14–15, and fetal livers were dissociated into single-cell suspensions. Genomic 
DNA from embryonic skin was used for genotyping by PCR (5). Adult 
  recipient RAG-2−/−/IL-2Rγ−/− mice received conditioning radiation from 
a cesium source (450 or 900 cGy), followed within 24 h by tail vein injection 
of 4 × 106 NF90+/+, NF90+/−, or NF90−/− fetal liver cells.
Flow cytometry. Engraftment and lymphocyte subsets in peripheral blood 
were monitored in NF90-RAG chimeric mice at 4 and 9 wk after transplan-
tation. Peripheral blood mononuclear cells were labeled with anti-CD4, 
-CD8, -CD19, and -DX5 antibodies (Becton Dickinson) and analyzed by 
fl  ow cytometry (LSR; Becton Dickinson) using FloJo software (TreeStar 
Inc.). NF90-RAGγ chimeras were killed at 15 wk after transplantation. 
  Dissociated thymic and spleen cells were labeled with anti-CD4, -CD8, 
-CD25, -CD11b, -CD11c, and -B220 antibodies (Becton Dickinson) and 
analyzed by fl  ow cytometry.
IL-2 analysis. Thymocytes, splenocytes, and CD4+ T cells (enriched 
by magnetic bead negative selection; Miltenyi Biotec) were stimulated 
(106 cells/ml) for 6–18 h with 20 ng/ml anti-CD3 (Becton Dickinson) + 
20 ng/ml anti-CD28 (Becton Dickinson) or 20 ng/ml PMA + 2 μM 
Iono, and supernatants were analyzed by IL-2 ELISA (Becton Dickinson) 
in triplicate.JEM VOL. 204, May 14, 2007  977
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ARRE/NFAT luciferase reporter gene assays. Primary thymocytes 
were isolated from newborn NF90+/+, NF90+/−, and NF90−/− littermate 
mice and cultured in vitro with 20 ng/ml anti-CD3 and 100 U/ml recom-
binant IL-2 (Becton Dickinson). After 3–7 d, 0.8 × 106 cells of each geno-
type were nucleofected (Amaxa) with 3× ARRE/NFAT fi  refl  y luciferase 
(3 μg) and EF-1α Renilla luciferase (1 μg) reporter genes. Jurkat T cells were 
stably transfected with expression plasmid pEF-1α NF90 ires neo and 
  selected in G418. Control or NF90 T cells were transiently transfected with 
ARRE/NFAT fi  refl  y and EF Renilla luciferase. After 18 h in culture, thy-
mocytes or Jurkat T cells were divided into nonstimulated and 6-h PMA/
Iono-stimulated pools, and cell lysates were analyzed for the ratios of fi  refl  y/
Renilla luciferase activities (Dual Luciferase Reporter; Promega).
Northwestern blotting. The radiolabeled IL-2 3′ UTR RNA probe was 
transcribed in vitro (nt 558–939 available from GenBank/EMBL/DDBJ 
  under accession no. NM_008366). 80 μg of brain extracts or 10 μg of 
  recombinant NF90 protein were fractionated by SDS-PAGE, transferred to 
nitrocellulose, and probed as previously described (5).
IL-2 mRNA stability. 0.7 × 106 splenocytes per condition from newborn 
NF90+/+ or NF90−/− mice (two littermate animals for each genotype) were 
nonstimulated, stimulated for 6 h with anti-CD3/CD28 (1 μg/ml each), 
or stimulated for 6 h followed by addition of 10 μg/ml actinomycin D 
for 30 min. Total RNA was extracted (TRIzol; Invitrogen) and reverse 
transcribed using oligo dT primer, and IL-2 and β-actin were amplifi  ed by 
PCR (35 cycles of 95°C for 20 s, 58°C for 40 s, and 72°C for 40 s) (5). The 
primer sequences used are IL-2 (forward) 5′-G  C  T  C  C  T  G  A  G  C  A  G  G  A  T  G-
G  A  G  A  A  T  T  A  C  A  G  -3′ and (reverse) 5′-G  A  G  A  G  C  C  T  T  A  T  G  T  G  T  T  G  T  A  A-
G  C  A  G  G  A  G  G  -3′. The intensities of the ethidium bromide–stained bands 
were quantifi  ed using ImageJ software (National Institutes of Health). The 
means of the relative intensities at 0 and 30 min of actinomycin D were 
averaged and used to calculate the IL-2 mRNA half-life, assuming fi  rst order 
exponential decay.
Data analysis. Data are presented as the mean ± SD. Statistical signifi  cance 
was determined by analysis of variance or the Student’s paired t test (Excel; 
Microsoft), and P < 0.05 was considered signifi  cant.
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